Comparative Pharmacology
Head-to-head clinical analysis: ARTESUNATE versus MALMOREDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARTESUNATE versus MALMOREDE.
ARTESUNATE vs MALMOREDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.
Malmorede is a synthetic peptide analog of thymosin alpha 1, acting as a biological response modifier. It enhances T-cell maturation and function, increases interleukin-2 production, and modulates immune response by activating dendritic cells and promoting Th1-type cytokine release.
2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.
Initial: 50 mg orally twice daily. Maintenance: 100 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateMethoxsalen + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Methoxsalen resulting in a loss in efficacy."
Clinical Note
moderateRifampicin + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Rifampicin resulting in a loss in efficacy."
Clinical Note
moderatePhenobarbital + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Phenobarbital resulting in a loss in efficacy."
Clinical Note
Terminal elimination half-life of artesunate is approximately 1 hour. The active metabolite dihydroartemisinin has a half-life of 1-2 hours. This short half-life supports rapid parasite clearance in severe malaria.
4-6 hours; increased in renal impairment (up to 12-15 hours).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% as unchanged drug. Biliary/fecal elimination is minimal. ~80% of the dose is recovered in urine as metabolites, mainly dihydroartemisinin.
Primarily renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Category C
Category C
Antimalarial
Antimalarial
Nevirapine + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Nevirapine resulting in a loss in efficacy."